Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Raised to $13.00 at B. Riley Financial

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price target lifted by B. Riley Financial from $11.00 to $13.00 in a research report sent to investors on Wednesday,Benzinga reports. B. Riley Financial currently has a buy rating on the stock.

A number of other equities research analysts have also weighed in on the stock. Truist Financial set a $12.00 target price on shares of Perspective Therapeutics in a research note on Tuesday. HC Wainwright increased their target price on Perspective Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Piper Sandler initiated coverage on shares of Perspective Therapeutics in a report on Thursday, February 19th. They set an “overweight” rating and a $16.00 price target on the stock. BTIG Research reiterated a “buy” rating and issued a $14.00 price objective on shares of Perspective Therapeutics in a report on Tuesday. Finally, Royal Bank Of Canada cut their target price on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $12.50.

Perspective Therapeutics Stock Performance

Shares of CATX stock opened at $4.86 on Wednesday. The company has a current ratio of 5.17, a quick ratio of 8.66 and a debt-to-equity ratio of 0.01. Perspective Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $6.16. The stock has a 50 day moving average price of $4.30 and a two-hundred day moving average price of $3.43.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.51) EPS for the quarter. The firm had revenue of $0.04 million for the quarter. Perspective Therapeutics had a negative net margin of 11,665.27% and a negative return on equity of 41.79%. As a group, research analysts forecast that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Institutional Trading of Perspective Therapeutics

Institutional investors have recently made changes to their positions in the business. Los Angeles Capital Management LLC purchased a new stake in Perspective Therapeutics during the second quarter valued at $61,000. Geode Capital Management LLC lifted its position in shares of Perspective Therapeutics by 15.8% during the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after purchasing an additional 188,887 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Perspective Therapeutics by 118.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock valued at $2,573,000 after buying an additional 405,612 shares during the period. Walleye Capital LLC boosted its holdings in shares of Perspective Therapeutics by 375.8% in the second quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock valued at $645,000 after purchasing an additional 148,013 shares during the period. Finally, Federated Hermes Inc. lifted its holdings in shares of Perspective Therapeutics by 44.4% in the 2nd quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock worth $671,000 after buying an additional 60,019 shares during the period. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics News Summary

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: B. Riley raised its price target from $11 to $13 and maintained a “Buy” rating — a sizeable upside projection that signals stronger sell‑side conviction in the company’s growth/clinical roadmap. B. Riley Price Target Raise
• Positive Sentiment: UBS raised its price target from $7 to $8 and kept a “Buy” rating, providing additional analyst support for upside potential. UBS Price Target Raise
• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating with an $11 target — another vote of confidence from a major biotech analyst. Wedbush Rating Reaffirmation
• Positive Sentiment: Perspective announced that updated data for its lead radiopharmaceutical, [212Pb]VMT-α-NET, was accepted for poster presentation at AACR 2026 — this raises scientific visibility and could help commercial/regulatory momentum if the data remain favorable. The company previously reported encouraging anti‑tumor activity (76% without progression in a subset) and no dose‑limiting toxicities in interim analyses. AACR Presentation Acceptance
• Neutral Sentiment: The company is scheduled to release quarterly earnings this week — an event that can be a catalyst for volatility as investors reassess cash runway, R&D spend and trial progress. Earnings Release Date
• Neutral Sentiment: Perspective published full‑year 2025 results and business highlights; these filings provide more detail on cash, operating burn and program timelines that investors will parse for runway and dilution risk. Full‑Year 2025 Results
• Negative Sentiment: Royal Bank of Canada trimmed its target from $18 to $14 (still “Outperform”) — a downward revision that could moderate upside expectations and trigger short‑term profit‑taking. RBC Target Lowered
• Negative Sentiment: Clinical safety data include Grade 3+ treatment‑emergent adverse events in ~37.5% of patients (one transient Grade 4 reported); these safety signals may temper enthusiasm until larger cohorts and confirmatory data are available. Clinical Safety Details

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.